Recombinant Human IGFBP-3 Protein, CF

Catalog # Availability Size / Price Qty
675-B3-025
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (11)
FAQs
Supplemental Products
Reviews

Recombinant Human IGFBP-3 Protein, CF Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF‑7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083. The ED50 for this effect is 0.05-0.15 µg/mL in the presence of 14 ng/mL Recombinant Human IGF‑II (Catalog # 292-G2).
Source
Mouse myeloma cell line, NS0-derived human IGFBP-3 protein
Gly28-Lys291, with an N-terminal Met
Accession #
N-terminal Sequence
Analysis
Met
Predicted Molecular Mass
29 kDa
SDS-PAGE
37-47 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

675-B3

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: IGFBP-3

Insulin-like growth factor binding protein-3 (IGFBP-3) is one of six members of the insulin­like growth factor (IGF) binding protein superfamily which function to modulate the biological activity of IGF (1). Human IGFBP-3 is the major binding protein of IGF where it exists in circulation as a ternary complex with the acid-labile subunit (ALS) (2). Like other IGFBP members, human IGFBP-3 includes a cysteine-rich C-terminal domain, a highly variable central linker domain, and another
N-terminal cysteine-­rich domain (2, 3). Human IGFBP­-3 cDNA encodes a 291 amino acid (aa) precursor protein with a 27 aa signal peptide that is processed to generate the 264 aa mature protein. Mature human IGFBP-3 shares 82% aa sequence identity with both mouse and rat IGFBP-3. Post-­translational glycosylation and phosphorylation of IGFBP-3 modifies the affinities of the binding protein. Proteolysis of IGFBP-3 by tissue plasminogen activator (tPA), a disintegrin and metaloproteases (ADAMs), and prostate specific antigen (PSA) contributes to IGFBP-3 degradation or a reduction in its affinity for IGF (4-6). The majority of soluble IGFBP-3 found in circulation is secreted from hepatic non-parenchymal cells. IGFBP-3 expression can be modulated by p53 as well as by various cytokines and growth factors (7, 8). In addition to its role in stabilizing and transporting circulating IGF, IGFBP-3 has been shown to potentiate EGF-EGFR-mediated cell growth through the activation of sphingosine kinase1 (SPHK1) and sphingosin-1-phosphate (S1P) (9, 10). IGFBP-3 has also been shown to modulate adipogenesis (11). Binding of IGFBP-3 to non-IGF-related ligands has been shown to regulate TGF-beta signaling, DNA damage, apoptosis, autophagy, and gene transcription (12). Interactions with non-IGF-related ligands is thought to contribute, in part, to the dichotomous stimulatory and inhibitory effects of IGFBP-3 on cell growth (2).

References
  1. Shimasaki, S. and N. Ling (1991) Prog. Growth Factor Res. 3:243.
  2. Baxter, R.C. (2013) J. Cell Commun. Signal 7:179.
  3. Baxter, R.C. (2014) Nat. Rev. Cancer 14:329.
  4. Mochizuki, S. et al. (2004) Biochem. Biophys. Res. Commun. 315:79.
  5. Cohen, P. et al. (1994) J. Endocrinol. 142:407.
  6. Bang, P. (1995) Prog. Growth Factor Res. 6:285.
  7. Perks, C.M. and J.M. Holly (2008) J. Mammary Gland Biol. Neoplasia 13:455.
  8. Chan, K. and E.M. Spencer (1997) Endocrine 7:95.
  9. Guix, M. et al. (2008) J. Clin. Invest. 118:2609.
  10. Martin, J.L. et al. (2009) J. Biol. Chem. 284:25542.
  11. Chan, S.S. et al. (2009) Am. J. Physiol. Endocrinol. Metab. 296:E654.
  12. Martin, J.L. and R.C. Baxter (2011) Growth Factors 29:235.
Long Name
Insulin-like Growth Factor Binding Protein 3
Entrez Gene IDs
3486 (Human); 16009 (Mouse)
Alternate Names
acid stable subunit of the 140 K IGF complex; binding protein 29; binding protein 53; growth hormone-dependent binding protein; IBP-3; IBP3BP-53; IGF-binding protein 3; IGFBP3; IGFBP-3; insulin-like growth factor binding protein 3; insulin-like growth factor-binding protein 3

Citations for Recombinant Human IGFBP-3 Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

11 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Differential expression of hypoxia-inducible factors related to the invasiveness of epithelial ovarian cancer
    Authors: HJ Shih, HF Chang, CL Chen, PL Torng
    Scientific Reports, 2021;11(1):22925.
    Species: Human
    Sample Types: Recombinant Proteins
    Applications: Bioassay
  2. Effects of Transport Duration and Environmental Conditions in Winter or Summer on the Concentrations of Insulin-Like Growth Factors and Insulin-Like Growth Factor-Binding Proteins in the Plasma of Market-Weight Pigs
    Authors: E Wirthgen, S Goumon, M Kunze, C Walz, M Spitschak, A Tuchschere, J Brown, C Höflich, L Faucitano, A Hoeflich
    Front Endocrinol (Lausanne), 2018;9(0):36.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Western Blot
  3. IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma
    Authors: Matthew N Svalina
    Sci Rep, 2016;6(0):27012.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Plasminogen activator inhibitor 1--insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence.
    Authors: Elzi, David J, Lai, Yanlai, Song, Meihua, Hakala, Kevin, Weintraub, Susan T, Shiio, Yuzuru
    Proc Natl Acad Sci U S A, 2012;109(30):12052-7.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis.
    Authors: Bogatkevich GS, Ludwicka-Bradley A, Highland KB, Hant F, Nietert PJ, Singleton CB, Feghali-Bostwick CA, Silver RM
    Arthritis Rheum., 2007;56(7):2432-42.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5.
    Authors: Cortesio CL, Jiang W
    Arch. Biochem. Biophys., 2006;449(1):164-70.
    Species: Human
    Sample Types: N/A
    Applications: Enzyme Assay
  7. IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells.
    Authors: Rosendahl AH, Forsberg G
    Kidney Int., 2006;70(9):1584-90.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. Mining the acute respiratory distress syndrome proteome: identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury.
    Authors: Schnapp LM, Donohoe S, Chen J, Sunde DA, Kelly PM, Ruzinski J, Martin T, Goodlett DR
    Am. J. Pathol., 2006;169(1):86-95.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  9. Thrombospondin 1, produced by endothelial cells under the action of erythropoietin, stimulates thymidine incorporation into erythroid cells and counteracts the inhibitory action of insulin-like growth factor binding protein 3.
    Authors: Congote LF, DiFalco MR, Gibbs BF
    Cytokine, 2005;30(5):248-53.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability.
    Authors: Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A
    Biochem. Biophys. Res. Commun., 2005;333(3):1011-6.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Enzyme Assay
  11. Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma.
    Authors: Kirman I, Poltoratskaia N, Sylla P, Whelan RL
    Surgery, 2004;136(2):205-9.
    Species: Mouse
    Sample Types: Cell Culture Supernates
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human IGFBP-3 Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human IGFBP-3 Protein, CF and earn rewards!

Have you used Recombinant Human IGFBP-3 Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review